HK1209439A1 - Interleukin-10 fusion proteins and uses thereof -10 - Google Patents
Interleukin-10 fusion proteins and uses thereof -10Info
- Publication number
- HK1209439A1 HK1209439A1 HK15110298.1A HK15110298A HK1209439A1 HK 1209439 A1 HK1209439 A1 HK 1209439A1 HK 15110298 A HK15110298 A HK 15110298A HK 1209439 A1 HK1209439 A1 HK 1209439A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- interleukin
- fusion proteins
- fusion
- proteins
- Prior art date
Links
- 102000003814 Interleukin-10 Human genes 0.000 title 1
- 108090000174 Interleukin-10 Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 229940076144 interleukin-10 Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179709 | 2012-08-08 | ||
| PCT/EP2013/066342 WO2014023673A1 (en) | 2012-08-08 | 2013-08-05 | Interleukin-10 fusion proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1209439A1 true HK1209439A1 (en) | 2016-04-01 |
Family
ID=48917543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15110298.1A HK1209439A1 (en) | 2012-08-08 | 2015-10-20 | Interleukin-10 fusion proteins and uses thereof -10 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9346872B2 (es) |
| EP (1) | EP2882774B1 (es) |
| JP (3) | JP2015530983A (es) |
| KR (1) | KR20150038012A (es) |
| CN (1) | CN104540848B (es) |
| AR (1) | AR092050A1 (es) |
| AU (1) | AU2013301656A1 (es) |
| BR (1) | BR112015002085A2 (es) |
| CA (1) | CA2876285A1 (es) |
| CL (1) | CL2014003605A1 (es) |
| CO (1) | CO7151522A2 (es) |
| CR (1) | CR20140565A (es) |
| EA (1) | EA201500208A1 (es) |
| HK (1) | HK1209439A1 (es) |
| IL (1) | IL236809A0 (es) |
| MA (1) | MA20150232A1 (es) |
| MX (1) | MX2015001675A (es) |
| PE (1) | PE20150645A1 (es) |
| PH (1) | PH12015500284A1 (es) |
| SG (1) | SG11201408526SA (es) |
| TW (1) | TW201418283A (es) |
| WO (1) | WO2014023673A1 (es) |
| ZA (1) | ZA201409304B (es) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013003361B8 (pt) | 2010-08-13 | 2022-01-25 | Roche Glycart Ag | Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| EP2950807B1 (en) | 2013-01-30 | 2018-03-28 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| KR20160083884A (ko) | 2013-11-01 | 2016-07-12 | 스페리움 바이오메드 에스.엘. | 치료제 및 미용제의 경피 전달을 위한 봉입체 |
| MX2016010174A (es) * | 2014-02-06 | 2016-11-15 | Hoffmann La Roche | Proteinas de fusion de interleucina-10 y usos de las mismas. |
| US10993990B2 (en) * | 2014-05-16 | 2021-05-04 | Baylor Research Institute | Methods and compositions for treating autoimmune and inflammatory conditions |
| AP2016009663A0 (en) | 2014-07-30 | 2016-12-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| EA036985B1 (ru) | 2014-10-31 | 2021-01-25 | НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. | Композиции и способы лечения метаболических расстройств |
| MX2017006250A (es) | 2014-11-14 | 2017-11-17 | Hoffmann La Roche | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf. |
| ES2824151T3 (es) | 2014-12-19 | 2021-05-11 | Alkermes Inc | Proteínas de fusión Fc monocatenarias |
| CN114751989A (zh) | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CN115746143A (zh) | 2015-10-02 | 2023-03-07 | 豪夫迈·罗氏有限公司 | 对共刺激性tnf受体特异性的双特异性抗体 |
| WO2017087768A1 (en) * | 2015-11-18 | 2017-05-26 | Duke University | Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes |
| WO2017093947A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
| CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
| PE20190126A1 (es) | 2016-03-31 | 2019-01-17 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos de uso de las mismas |
| CA3026393C (en) * | 2016-06-22 | 2023-03-14 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| CN112142859A (zh) * | 2017-05-22 | 2020-12-29 | 杭州博虎生物科技有限公司 | 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用 |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| MX2019014023A (es) | 2017-05-24 | 2020-02-17 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer. |
| EP3688023A4 (en) * | 2017-09-25 | 2021-06-30 | Dingfu Biotarget Co., Ltd | PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT |
| WO2019057180A1 (en) * | 2017-09-25 | 2019-03-28 | Dingfu Biotarget Co., Ltd. | PROTEIN HETÉRODIMÈRE AND USE THEREOF |
| CA3108949A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CN113015744A (zh) | 2018-08-30 | 2021-06-22 | Hcw生物科技公司 | 单链嵌合多肽和多链嵌合多肽以及其用途 |
| CA3108951A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| TW202033766A (zh) * | 2018-11-26 | 2020-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素１０變體及其衍生物 |
| US11084857B2 (en) | 2018-12-05 | 2021-08-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Nsp-interleukin-10 proteins and uses thereof |
| US20220144911A1 (en) * | 2019-02-01 | 2022-05-12 | Uab Research Foundation | Methods and compositions for il10 signaling antagonism |
| EP3927728A2 (en) | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| WO2020181235A1 (en) * | 2019-03-06 | 2020-09-10 | Deka Biosciences, Inc. | Il-10 variant molecules and methods of treating inflammatory disease and oncology |
| CN111909276A (zh) * | 2019-05-10 | 2020-11-10 | 复旦大学 | 一种融合蛋白及其用途 |
| KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
| JP2022537054A (ja) | 2019-06-21 | 2022-08-23 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| KR20210006300A (ko) * | 2019-07-08 | 2021-01-18 | 주식회사 프로젠 | 신규 알러지 질환 치료용 약학적 조성물 |
| JP7497417B2 (ja) * | 2019-07-08 | 2024-06-10 | プロジェン・カンパニー・リミテッド | 新規ｉｌ－１０変異体タンパク質及びその用途 |
| KR20210006301A (ko) * | 2019-07-08 | 2021-01-18 | 주식회사 프로젠 | 신규 융합단백질 및 그의 용도 |
| CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
| CN112618698B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白的注射制剂 |
| WO2021163369A2 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| JP2023519107A (ja) | 2020-02-11 | 2023-05-10 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 制御性ｔ細胞を活性化する方法 |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| MX2022014239A (es) | 2020-05-12 | 2023-02-09 | Regeneron Pharma | Nuevos agonistas de il10 y metodos para su uso. |
| KR20210141406A (ko) * | 2020-05-14 | 2021-11-23 | 주식회사 프로젠 | 신규 재조합 융합단백질 및 그의 용도 |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
| WO2022020324A1 (en) * | 2020-07-20 | 2022-01-27 | Viela Bio, Inc. | Immunocytokines for treatment of autoimmune and inflammatory conditions |
| JP2023534847A (ja) | 2020-07-20 | 2023-08-14 | デカ バイオサイエンシーズ， インコーポレイテッド | Ｉｌ－１０を含む二重サイトカイン融合タンパク質 |
| EP4259644A1 (en) * | 2020-12-10 | 2023-10-18 | Joint Stock Company "Biocad" | Immunocytokine for activating human il-10ra receptor and use thereof |
| KR20220099656A (ko) * | 2021-01-07 | 2022-07-14 | 주식회사 프로젠 | 신규 il-10 변이체 융합단백질 생산용 세포주 및 그의 용도 |
| EP4284819A1 (en) * | 2021-02-01 | 2023-12-06 | Askgene Pharma, Inc. | Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide |
| CN116063570A (zh) * | 2021-11-02 | 2023-05-05 | 广东菲鹏制药股份有限公司 | Il10单体融合蛋白及其应用 |
| WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (de) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Ohrring |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| AU2005272993B2 (en) | 2004-07-15 | 2010-02-11 | Xencor, Inc | Optimized Fc variants |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2007128563A1 (en) * | 2006-05-08 | 2007-11-15 | Philogen Spa | Antibody-targeted cytokines for therapy |
| PL3281952T3 (pl) * | 2007-10-30 | 2020-11-16 | Philogen S.P.A. | Antygen związany z reumatoidalnym zapaleniem stawów |
| WO2010005389A1 (en) * | 2008-07-11 | 2010-01-14 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
| SG178443A1 (en) | 2009-08-17 | 2012-04-27 | Roche Glycart Ag | Targeted immunoconjugates |
| BR112013003361B8 (pt) | 2010-08-13 | 2022-01-25 | Roche Glycart Ag | Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo |
| EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| MX2016010174A (es) | 2014-02-06 | 2016-11-15 | Hoffmann La Roche | Proteinas de fusion de interleucina-10 y usos de las mismas. |
-
2013
- 2013-08-05 MA MA37793A patent/MA20150232A1/fr unknown
- 2013-08-05 WO PCT/EP2013/066342 patent/WO2014023673A1/en active Application Filing
- 2013-08-05 JP JP2015525845A patent/JP2015530983A/ja active Pending
- 2013-08-05 EA EA201500208A patent/EA201500208A1/ru unknown
- 2013-08-05 CN CN201380041222.1A patent/CN104540848B/zh active Active
- 2013-08-05 SG SG11201408526SA patent/SG11201408526SA/en unknown
- 2013-08-05 EP EP13745407.0A patent/EP2882774B1/en active Active
- 2013-08-05 KR KR1020157003225A patent/KR20150038012A/ko not_active Application Discontinuation
- 2013-08-05 MX MX2015001675A patent/MX2015001675A/es unknown
- 2013-08-05 BR BR112015002085A patent/BR112015002085A2/pt not_active Application Discontinuation
- 2013-08-05 AU AU2013301656A patent/AU2013301656A1/en not_active Abandoned
- 2013-08-05 CA CA2876285A patent/CA2876285A1/en not_active Abandoned
- 2013-08-05 PE PE2015000169A patent/PE20150645A1/es not_active Application Discontinuation
- 2013-08-05 US US13/959,051 patent/US9346872B2/en active Active
- 2013-08-06 AR ARP130102781A patent/AR092050A1/es unknown
- 2013-08-07 TW TW102128385A patent/TW201418283A/zh unknown
-
2014
- 2014-12-05 CR CR20140565A patent/CR20140565A/es unknown
- 2014-12-12 CO CO14273530A patent/CO7151522A2/es unknown
- 2014-12-17 ZA ZA2014/09304A patent/ZA201409304B/en unknown
- 2014-12-31 CL CL2014003605A patent/CL2014003605A1/es unknown
-
2015
- 2015-01-19 IL IL236809A patent/IL236809A0/en unknown
- 2015-02-09 PH PH12015500284A patent/PH12015500284A1/en unknown
- 2015-10-20 HK HK15110298.1A patent/HK1209439A1/xx not_active IP Right Cessation
-
2016
- 2016-04-27 US US15/140,414 patent/US10040843B2/en active Active
-
2018
- 2018-10-05 JP JP2018190250A patent/JP6985232B2/ja active Active
-
2021
- 2021-01-26 JP JP2021009946A patent/JP2021087426A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US9346872B2 (en) | 2016-05-24 |
| MX2015001675A (es) | 2015-04-10 |
| CA2876285A1 (en) | 2014-02-13 |
| AR092050A1 (es) | 2015-03-18 |
| KR20150038012A (ko) | 2015-04-08 |
| BR112015002085A2 (pt) | 2017-12-19 |
| CO7151522A2 (es) | 2014-12-29 |
| CN104540848B (zh) | 2019-05-31 |
| IL236809A0 (en) | 2015-03-31 |
| MA20150232A1 (fr) | 2015-07-31 |
| SG11201408526SA (en) | 2015-03-30 |
| ZA201409304B (en) | 2017-09-27 |
| JP2015530983A (ja) | 2015-10-29 |
| TW201418283A (zh) | 2014-05-16 |
| JP2019033755A (ja) | 2019-03-07 |
| CN104540848A (zh) | 2015-04-22 |
| JP2021087426A (ja) | 2021-06-10 |
| EA201500208A1 (ru) | 2015-07-30 |
| US20160340413A1 (en) | 2016-11-24 |
| US10040843B2 (en) | 2018-08-07 |
| PH12015500284A1 (en) | 2015-04-27 |
| CL2014003605A1 (es) | 2015-04-06 |
| WO2014023673A1 (en) | 2014-02-13 |
| EP2882774B1 (en) | 2018-10-03 |
| AU2013301656A1 (en) | 2015-01-15 |
| US20140044674A1 (en) | 2014-02-13 |
| PE20150645A1 (es) | 2015-05-11 |
| JP6985232B2 (ja) | 2021-12-22 |
| EP2882774A1 (en) | 2015-06-17 |
| CR20140565A (es) | 2015-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1209439A1 (en) | Interleukin-10 fusion proteins and uses thereof -10 | |
| HK1251589A1 (zh) | 靶向/免疫調節性融合蛋白及其製造方法 | |
| HK1208827A1 (en) | Interleukin-2 fusion proteins and uses thereof -2 | |
| HK1205746A1 (en) | Interleukin-10 polypeptide conjugates and their uses -10 | |
| HK1214739A1 (zh) | 工程化的分泌蛋白質和方法 | |
| EP2877854A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
| EP2870170A4 (en) | NOVEL PEPTIDES AND THEIR USE | |
| EP2877205A4 (en) | MULTIMERIC FUSION PROTEIN VACCINE AND IMMUNOTHERAPEUTIC PRODUCT | |
| EP2968551A4 (en) | FUSION PROTEINS AND METHOD THEREFOR | |
| SG11201500111VA (en) | Peptides and uses thereof | |
| SG10201500208SA (en) | Npp1 fusion proteins | |
| SG10201701828WA (en) | Peptides and their uses | |
| SG11201403852UA (en) | Fused pyrroledicarboxamides and their use as pharmaceuticals | |
| EP2711376A4 (en) | FGFR-FC FUSION PROTEIN AND USE THEREOF | |
| HK1205524A1 (en) | Engineered conformationally-stabilized proteins | |
| EP2930189A4 (en) | CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF | |
| EP2825548A4 (en) | MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF | |
| EP2718432A4 (en) | NUCLEASE FUSION PROTEIN AND USES THEREOF | |
| SG10201507721SA (en) | CHO-GMT Recombinant Protein Expression | |
| GB201213672D0 (en) | Protein | |
| HK1211952A1 (en) | Recombinant protein | |
| AU2012901619A0 (en) | Fusion Proteins and Use Thereof | |
| GB201204065D0 (en) | Fusion polypeptide | |
| GB201214769D0 (en) | Methodsa and peptides | |
| GB201215901D0 (en) | Protein modification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230803 |